|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
44,500,000 |
Market
Cap: |
224.73(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.78 - $10.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE silencing technology.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,447 |
29,851 |
83,116 |
204,188 |
Total Sell Value |
$6,309 |
$149,864 |
$489,708 |
$2,829,450 |
Total People Sold |
1 |
12 |
13 |
15 |
Total Sell Transactions |
1 |
12 |
15 |
48 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2021-05-17 |
4 |
AS |
$31.66 |
$189,960 |
D/D |
(6,000) |
68,871 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2021-05-17 |
4 |
OE |
$5.31 |
$31,860 |
D/D |
6,000 |
74,871 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2021-05-12 |
4 |
AS |
$32.29 |
$72,653 |
D/D |
(2,250) |
263,927 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2021-04-15 |
4 |
AS |
$35.06 |
$210,360 |
D/D |
(6,000) |
68,871 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2021-04-15 |
4 |
OE |
$5.31 |
$31,860 |
D/D |
6,000 |
74,871 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2021-04-14 |
4 |
AS |
$35.07 |
$188,518 |
D/D |
(5,350) |
266,177 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2021-03-17 |
4 |
AS |
$32.95 |
$74,617 |
D/D |
(2,250) |
271,527 |
|
- |
|
Gut Robert |
Director |
|
2021-03-02 |
4 |
S |
$36.98 |
$48,074 |
D/D |
(1,300) |
42,001 |
|
- |
|
Soteropoulos Paula |
Director |
|
2021-03-02 |
4 |
S |
$37.60 |
$18,950 |
D/D |
(504) |
6,364 |
|
- |
|
Astley-Sparke Philip |
Director |
|
2021-03-02 |
4 |
S |
$37.60 |
$18,950 |
D/D |
(504) |
9,946 |
|
- |
|
Balachandran Madhavan |
Director |
|
2021-03-02 |
4 |
S |
$37.50 |
$18,938 |
D/D |
(505) |
9,945 |
|
- |
|
Kaye Jack |
Director |
|
2021-03-02 |
4 |
S |
$37.60 |
$18,950 |
D/D |
(504) |
18,069 |
|
- |
|
Klemt Christian |
Chief Accounting Officer |
|
2021-03-02 |
4 |
S |
$37.03 |
$49,991 |
D/D |
(1,350) |
63,604 |
|
- |
|
Springhorn Jeremy P. |
Director |
|
2021-03-02 |
4 |
S |
$37.50 |
$18,938 |
D/D |
(505) |
9,945 |
|
- |
|
Meek David D. |
Director |
|
2021-03-02 |
4 |
S |
$37.50 |
$18,938 |
D/D |
(505) |
6,448 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2021-03-02 |
4 |
S |
$37.00 |
$44,622 |
D/D |
(1,206) |
68,871 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2021-03-02 |
4 |
S |
$36.94 |
$183,740 |
D/D |
(4,974) |
273,777 |
|
- |
|
Post Leonard E |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
2,382 |
|
- |
|
Gut Robert |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
43,301 |
|
- |
|
Springhorn Jeremy P. |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
10,450 |
|
- |
|
Soteropoulos Paula |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
6,868 |
|
- |
|
Klemt Christian |
Chief Accounting Officer |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,335 |
64,954 |
|
- |
|
Meek David D. |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
6,953 |
|
- |
|
Balachandran Madhavan |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
10,450 |
|
- |
|
Astley-Sparke Philip |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
10,450 |
|
- |
|
336 Records found
|
|
Page 6 of 14 |
|
|